Rosacea is a clinically common chronic inffammatory skin disease with complex pathogenesis, protracted course and frequent recurrence. Traditional therapeutic regimens have limited efffcacy and often face the problem of drug resistance. Janus kinase (JAK) inhibitors can speciffcally block the JAK-STAT signaling pathway and precisely regulate inffammatory and immune responses, which have shown definite efficacy in a variety of immune-related skin diseases. This paper systematically reviews the correlation between the JAK-STAT signaling pathway and rosacea, the mechanism of action of JAK inhibitors, the clinical application and safety of commonly used drugs, aiming to clarify the value and potential of JAK inhibitors in the treatment of rosacea and provide references for clinical targeted therapy.